Dosing & Uses
This drug has been discontinued in the United States
Serious - Use Alternative
Significant - Monitor Closely
Unresponsiveness to tactile or nociceptive stimuli
Situations where general anesthesia is contraindicated
May cause loss of spontaneous respiration, hypoxemia, hypotension
Not recommended for labor & delivery
Caution in respiratory disease
Patient may become unresponsive or minimally responsive to painful stimuli
Caution in hepatic or renal impairment
Pregnancy & Lactation
Pregnancy Category: B
Lactation: enters breast milk; not recommended
A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA:Information not available.
Mechanism of Action
Sedative-hypnotic, prodrug of propofol; interacts with GABA A receptor
Peak Plasma Time: 2-4 min to propofol; 8-12 min of propofol from fospropofol:
Protein Bound: 98%
Onset: ~8 min
Half-life: 0.8-0.96 hr
Duration: ~5 min (time to fully alert)
Vd: 0.26-0.4 L/kg
Metabolism: by alk phos to propofol, formaldehyde & phosphate
IV Incompatibilities: midazolam; meperidine
Administer through a secure, freely flowing, peripheral line
Flush infusion line with NS before & after administration
Compatible common fluids: D5W, D5/0.2%NaCl, D5/0.5NS, D5/LR, LR, NS, 0.5NS
Do not coadminister other drugs